Drug Profile
RP 71955
Latest Information Update: 18 Nov 1994
Price :
$50
*
At a glance
- Originator Aventis
- Class Antivirals
- Mechanism of Action Aspartic endopeptidase inhibitors; HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 18 Nov 1994 Discontinued-Preclinical for HIV-1 infections in France (Unknown route)